Apremilast: A new hope in psoriasis

Journal Title: IP Indian Journal of Clinical and Experimental Dermatology - Year 2018, Vol 4, Issue 3

Abstract

Introduction Psoriasis is a common chronic inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted due to chronicity of the disease and frequent remissions and relapse There is a vast array of drugs for the treatment Methotrexate cyclosporine and retinoids are the most commonly used conventional systemic drugs Newer studies provide insight into their more effective and safer use and as combination therapy with biologics Apremilast is an orally administered small molecule inhibitor of phosphodiesterase 4 PDE4 Apremilast 30mg twice daily reduced the severity of moderate to severe plaque psoriasis palmoplantar psoriasis and guttate psoriasisObjective To evaluate efficacy tolerability and adverse effects of apremilastMaterials and Methods A clinical trail was conducted in department of Skin VD of Saraswathi institute of medical college on 80 patients Apremilast was started after initial titration and followed for 8 weeksResults Out of 80 patients 73 patients completed the study of which 69 patients have responded well and 14 patient did not show satisfactory result No major side effect encountered during the studyConclusion Apremilast was effective in plaque psoriasis palmo plantar psoriasis and guttate psoriasis and is well tolerated with mild adverse effects Also the regular lab investigations as required in others systemic treatment modalities are avoidedKeywords Apremilast Plaque psoriasis Phosphodiesterase 4 PDE4 Guttate psoriasis Palmo plantar psoriasis

Authors and Affiliations

Sachin Agarwal, Amarjeet Singh Verma, Prashant Kumar Yadav, Megha Sharma, Harmeet Kaur

Keywords

Related Articles

An Evaluation of Patch Test among Hand Eczema Patients Attending Tertiary Care Center in South East Rajasthan

Abstract Context: Hand eczema is one of the most common occupational dermatological condition. Chronicity and recurrence nature of hand eczema leads to loss of work and quality of life of workers. In order to identify th...

A study of shape of ulnar nerve in leprosy patients

Background: The most common nerve affected in leprosy is ulnar nerve, which show enlargement and inflammation. Aims: To study shape of ulnar nerve (UN) in the cubital tunnel and to evaluate the role of high-resolution ul...

Evaluation of various chemical peels in facial melanosis

Introduction: Chemical peeling is a preferred, generally safe and relatively economic day procedure for pigmentary skin disorders and for skin revival. Aim: Evaluation of various chemical peels (Salicylic acid, Trichloro...

A 5 year study of leprosy patients in a tertiary care centre

Introduction The implementation of MDT has resulted in bringing the national prevalence down to elimination of less than 110000 in December 2005 and even further down to 06610000 in 2016 This study highlights the demogra...

Dermatological manifestations of chronic venous insufficiency: A cross-sectional study from a Centre in South India

Background: Chronic venous insufficiency (CVI) describes a condition that affects the venous system of the lower extremities with venous hypertension causing various pathologies including pain, edema, skin changes and ul...

Download PDF file
  • EP ID EP488896
  • DOI 10.18231/2581-4729.2018.0045
  • Views 134
  • Downloads 0

How To Cite

Sachin Agarwal, Amarjeet Singh Verma, Prashant Kumar Yadav, Megha Sharma, Harmeet Kaur (2018). Apremilast: A new hope in psoriasis. IP Indian Journal of Clinical and Experimental Dermatology, 4(3), 212-214. https://europub.co.uk/articles/-A-488896